Canaccord Genuity maintains Ultragenyx Pharmaceutical at Buy, lowers price target to $34 from $39
Canaccord Genuity maintained its Buy rating on Ultragenyx Pharmaceutical but lowered its price target to $34 from $39. The new target suggests a 98.1% upside from the Nov 4 close of $17.16. Recent analyst price targets for the company range from $17 to $22.
How this was made

The 30-second read
Why it matters
The downgrade reflects concerns about growth prospects and may trigger short‑term selling.
Market read
A modest analyst downgrade with limited immediate market impact.
What to watch
Potential upcoming clinical trial data could offset the downgrade.
Background
Ultragenyx is a rare‑disease biotech; analyst price‑target changes are common but can move the stock.
Market effects
Minor impact on biotech sector sentiment.
Limited to US biotech investors.
Low global relevance.
Counterpoint
The target cut may be overly cautious given recent pipeline progress.
Key entities
- Analyst FirmCanaccord Genuity
Provided the revised price target.
- CompanyUltragenyx Pharmaceutical
Subject of the analyst downgrade.

